Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-Ovarian05: R-DXd with or without bevacizumab versus platinum-based doublet chemotherapy with or without bevacizumab in platinum-sensitive ovarian cancer after first-line PARPi progression
jRCT2060260074Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing R-DXd +/- Bevacizumab with Standard of Care (2 arms). Primary endpoints: Progression-Free Survival and Overall Survival. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
raludotatug deruxtecanbevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2060260074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2060260074.